Why are some EU5 HCV brands standing out more than others?
There are various options available to EU5 infectious diseases specialists and primary care physicians (PCPs) treating hepatitis C virus infection (HCV). Clearly some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors
NPS+ HCV (EU5) gives a unique insight into the overall brand health of 8 leading treatments for HCV currently being used in the EU5 markets. 150 infectious diseases specialists and PCPs were surveyed on key issues including brand messaging, prescribing behaviour and satisfaction levels. The results provide valuable insight for brand marketers seeking new ways to stand out.
Top Takeaways • Only four brands get positive NPS. In Europe, 4 of the 8 brands surveyed obtained positive brand health scores, but just barely. In contrast, brands languishing at the bottom of the table scored huge negative scores. Where is your brand, and what could you do about it? • Brand loyalty is difficult to come by. Loyalty scores of less than 3 indicate low loyalty, and none of the brands surveyed managed to score above this magic number. Is clinical differentiation really that low? • Satisfaction scores also low. EU5 physicians aren’t as satisfied as their US counterparts, it would seem. What’s causing this low level of satisfaction, and is it being felt across all brands, or just a small selection? • Is there a dominant brand message? Find out which messages are resonating with physicians, and take your brand’s positioning strategy to another level. • In their own words. What do doctors say each brand means to them? For example, which brand is described as ‘my drug of choice’ and which brand is dubbed as ‘outrageously expensive’?
NPS+ HCV (EU5) offers valuable insight into brand loyalty from the perspective of those currently prescribing treatments for HCV to patients. You’ll discover: • How loyal doctors are to your brand. • How many other brands your Promoters recommend. • Which other brands your Promoters and Detractors recommend. • How much market share your brand has among Promoters and Detractors. • How much market share you stand to gain by converting Detractors into Promoters. • Which messages Promoters, Passives and Detractors associate with your brand. • Your brand DNA: what doctors really think of your brand—in their own words.
A Report Based on Expert Knowledge
We surveyed 150 neurologists across the EU5 (France, Italy, Germany, Spain, UK) chosen from the largest community of validated physicians in the world. We conducted the survey between January 10-23, 2018.
What is Net Promoter® Score?
NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.
How does NPS work?
NPS measures overall brand satisfaction and loyalty by asking one simple question: "How likely are you to recommend this brand to a colleague?"
Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories: • Detractors are those who answer 0 – 6. • Passives are those who answer 7 – 8. • Promoters are those who answer 9 - 10.
How is NPS calculated?
The percentage of detractors - the percentage of promoters = NPS.
For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.
NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.
What is FirstView NPS+?
NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.
Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.
Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.
Our reports have been used by over 10K customers, including:
2020-2025 Database: France Blood Typing, Grouping and Infectious Disease NAT Screening Database: Supplier Shares, Volume and Sales Segment Forecasts for over 40 Tests This database provides the 2020 supplier shares, the 2020-2025 volume and sales forecasts for over 40 tests, as well as comprehensive lists of companies...
2024 Emerging US Diagnostic Testing Market: Supplier Shares by Test and Segment Sales Forecasts This new report provides an overview of the US diagnostic testing market.The report is available by section, and can be customized to specific information needs and budget, including sales and market shares of leading...
Anal Cancer - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H2 2020, provides an overview of the Anal Cancer (Oncology) pipeline landscape. Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal...
2024 UK Diagnostics Market for 500 Tests: Supplier Shares by Test, Volume and Sales Segment Forecasts, Analysis of Leading Competitors This new report provides an overview of the UK diagnostic testing market, is available by section, and can be customized to specific information needs and budget.The report...
2024 Japan In Vitro Diagnostics Market for 500 Tests: Instrument and Reagent Supplier Shares, Volume and Sales Segment Forecasts, Business Environment, Market Structure, Competitive Landscape, Innovative Technologies, Instrumentation Review, Opportunities for Suppliers This new report provides an overview of the...
2024 U.K. Transfusion Diagnostics Market: Immunohematology and NAT Testing--Supplier Shares and Strategies, Innovative Technologies, Instrumentation Review, Emerging Opportunities This new report is a strategic analysis prepared in order to help current suppliers and potential market entrants identify and evaluate...
Oropharyngeal Cancer - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2020, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape. Oropharyngeal cancer is a disease which...
Hepatitis D - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Pipeline Review, H2 2020, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape. Hepatitis D, also known as the delta virus, is an infection...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.